iShares Biotechnology ETF
649 hedge funds and large institutions have $4.6B invested in iShares Biotechnology ETF in 2018 Q4 according to their latest regulatory filings, with 112 funds opening new positions, 154 increasing their positions, 253 reducing their positions, and 83 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
less funds holding in top 10
Funds holding in top 10: →
27% less capital invested
Capital invested by funds: $6.3B → $4.6B (-$1.7B)
39% less repeat investments, than reductions
Existing positions increased: 154 | Existing positions reduced: 253
47% less call options, than puts
Call options by funds: $321M | Put options by funds: $610M
Holders
649
Holding in Top 10
18
Calls
$321M
Puts
$610M
Top Buyers
| 1 | +$58.8M | |
| 2 | +$41M | |
| 3 | +$40.7M | |
| 4 |
LMIM
Lockheed Martin Investment Management
Bethesda,
Maryland
|
+$25.6M |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$18M |
Top Sellers
| 1 | -$138M | |
| 2 | -$127M | |
| 3 | -$93.4M | |
| 4 |
DFO
Duquesne Family Office
New York
|
-$65.8M |
| 5 |
Goldman Sachs
New York
|
-$58.1M |